Pfizer Focusing Obesity Rx Development Efforts On Combination Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
The company's antihypertensive/cholesterol-lowering agent Caduet and the atorvastatin/torcetrapib combination have potential for use in metabolic syndrome, Pfizer VP-Cardiovascular Medical Group Palmer says. Future obesity therapies will require comparable efficacy to Abbott's Meridia but with a more tolerable safety profile, he says.
You may also be interested in...
Drug Development For Metabolic Syndrome Is Stunted By Inadequate Definitions
Pfizer's Fryburg says treatment of the syndrome may not offer benefit over treatment of individual disease components.
Drug Development For Metabolic Syndrome Is Stunted By Inadequate Definitions
Pfizer's Fryburg says treatment of the syndrome may not offer benefit over treatment of individual disease components.
Obesity Market Could Add Two New Therapies In The Near Term, Pfizer Says
The obesity drug market could potentially see two new entrants in the near term, Pfizer VP-U.S. Cardiovascular Medical Group Gary Palmer, MD, said Dec. 1 at the Health Care Research & Innovations Congress in Washington, D.C